Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.

Kodama N, Tahara N, Tahara A, Honda A, Nitta Y, Mizoguchi M, Kaida H, Ishibashi M, Abe T, Ikeda H, Narula J, Fukumoto Y, Yamagishi S, Imaizumi T.

J Clin Endocrinol Metab. 2013 Nov;98(11):4438-45. doi: 10.1210/jc.2013-2920. Epub 2013 Sep 12.

PMID:
24030946
2.

Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.

Nitta Y, Tahara N, Tahara A, Honda A, Kodama N, Mizoguchi M, Kaida H, Ishibashi M, Hayabuchi N, Ikeda H, Yamagishi S, Imaizumi T.

JACC Cardiovasc Imaging. 2013 Nov;6(11):1172-82. doi: 10.1016/j.jcmg.2013.09.004.

3.

Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.

Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, Mawatari K, Yasukawa H, Kaida H, Ishibashi M, Hayabuchi N, Harada H, Ikeda H, Yamagishi S, Imaizumi T.

JACC Cardiovasc Imaging. 2011 Oct;4(10):1110-8. doi: 10.1016/j.jcmg.2011.08.007.

4.
5.

Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

Elkhawad M, Rudd JH, Sarov-Blat L, Cai G, Wells R, Davies LC, Collier DJ, Marber MS, Choudhury RP, Fayad ZA, Tawakol A, Gleeson FV, Lepore JJ, Davis B, Willette RN, Wilkinson IB, Sprecher DL, Cheriyan J.

JACC Cardiovasc Imaging. 2012 Sep;5(9):911-22. doi: 10.1016/j.jcmg.2012.02.016.

6.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
7.

Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography.

Kim TN, Kim S, Yang SJ, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM.

Circ Cardiovasc Imaging. 2010 Mar;3(2):142-8. doi: 10.1161/CIRCIMAGING.109.888909. Epub 2010 Jan 8.

8.

Clinical and biochemical factors associated with area and metabolic activity in the visceral and subcutaneous adipose tissues by FDG-PET/CT.

Tahara N, Yamagishi S, Kodama N, Tahara A, Honda A, Nitta Y, Igata S, Matsui T, Takeuchi M, Kaida H, Kurata S, Abe T, Fukumoto Y.

J Clin Endocrinol Metab. 2015 May;100(5):E739-47. doi: 10.1210/jc.2014-3896. Epub 2015 Feb 19.

PMID:
25695885
9.

Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.

Derosa G, Mereu R, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Palumbo I, Maffioli P, Randazzo S, Cicero AF.

J Clin Pharm Ther. 2010 Oct;35(5):565-79. doi: 10.1111/j.1365-2710.2009.01132.x.

PMID:
20831680
10.

Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.

Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA.

Metabolism. 2005 Jan;54(1):24-32.

PMID:
15562376
11.

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.

Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T.

Diabet Med. 2005 Aug;22(8):980-5.

PMID:
16026361
12.

Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment.

Moon JH, Kim HJ, Kim SK, Kang ES, Lee BW, Ahn CW, Lee HC, Cha BS.

Metabolism. 2011 Feb;60(2):165-72. doi: 10.1016/j.metabol.2009.12.007. Epub 2010 Jan 22.

PMID:
20092860
13.

Increased glucose uptake in visceral versus subcutaneous adipose tissue revealed by PET imaging.

Christen T, Sheikine Y, Rocha VZ, Hurwitz S, Goldfine AB, Di Carli M, Libby P.

JACC Cardiovasc Imaging. 2010 Aug;3(8):843-51. doi: 10.1016/j.jcmg.2010.06.004. Erratum in: JACC Cardiovasc Imaging. 2014 Mar;7(3):336.

14.

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA.

J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91.

PMID:
12050251
15.

Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.

Tan M, Johns D, González Gálvez G, Antúnez O, Fabián G, Flores-Lozano F, Zúñiga Guajardo S, Garza E, Morales H, Konkoy C, Herz M; GLAD Study Group.

Clin Ther. 2004 May;26(5):680-93.

PMID:
15220012
16.

Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.

van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M.

Circulation. 2009 Apr 21;119(15):2069-77. doi: 10.1161/CIRCULATIONAHA.108.803916. Epub 2009 Apr 6.

17.

A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes.

Hiroi S, Sugiura K, Matsuno K, Hirayama M, Kuriyama K, Kaku K, Kawakami K.

Diabetes Technol Ther. 2013 Feb;15(2):158-65. doi: 10.1089/dia.2012.0246. Epub 2013 Jan 5.

PMID:
23289434
18.

Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.

Maffioli P, Fogari E, D'Angelo A, Perrone T, Derosa G.

Eur J Gastroenterol Hepatol. 2013 Sep;25(9):1113-22. doi: 10.1097/MEG.0b013e3283608317.

PMID:
23524525
19.

Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes.

Tahara N, Yamagishi S, Mizoguchi M, Tahara A, Imaizumi T.

Rejuvenation Res. 2013 Oct;16(5):344-51. doi: 10.1089/rej.2013.1434.

PMID:
23777507
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk